9 Meters Biopharma (NMTR) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NMTR vs. TTNP, MBRX, DRMA, EVOK, VIVS, THAR, PLRZ, CERO, CANF, and CMNDShould you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include Titan Pharmaceuticals (TTNP), Moleculin Biotech (MBRX), Dermata Therapeutics (DRMA), Evoke Pharma (EVOK), VivoSim Labs (VIVS), Tharimmune (THAR), Polyrizon (PLRZ), CERo Therapeutics (CERO), Can-Fite BioPharma (CANF), and Clearmind Medicine (CMND). These companies are all part of the "pharmaceutical products" industry. 9 Meters Biopharma vs. Its Competitors Titan Pharmaceuticals Moleculin Biotech Dermata Therapeutics Evoke Pharma VivoSim Labs Tharimmune Polyrizon CERo Therapeutics Can-Fite BioPharma Clearmind Medicine 9 Meters Biopharma (NASDAQ:NMTR) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability. Do institutionals and insiders have more ownership in NMTR or TTNP? 22.3% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are held by institutional investors. 2.4% of 9 Meters Biopharma shares are held by company insiders. Comparatively, 0.7% of Titan Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor NMTR or TTNP? In the previous week, Titan Pharmaceuticals had 3 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 3 mentions for Titan Pharmaceuticals and 0 mentions for 9 Meters Biopharma. Titan Pharmaceuticals' average media sentiment score of 0.45 beat 9 Meters Biopharma's score of 0.00 indicating that Titan Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment 9 Meters Biopharma Neutral Titan Pharmaceuticals Neutral Is NMTR or TTNP more profitable? Titan Pharmaceuticals' return on equity of -145.92% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets 9 Meters BiopharmaN/A -584.97% -159.45% Titan Pharmaceuticals N/A -145.92%-129.20% Which has more risk and volatility, NMTR or TTNP? 9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Which has higher valuation & earnings, NMTR or TTNP? Titan Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma. Titan Pharmaceuticals is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/ATitan Pharmaceuticals$180K22.24-$4.71M-$4.59-0.96 SummaryTitan Pharmaceuticals beats 9 Meters Biopharma on 7 of the 11 factors compared between the two stocks. Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMTR vs. The Competition Export to ExcelMetric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$127.87M$5.54B$9.05BDividend YieldN/A3.74%5.24%4.02%P/E Ratio-0.023.4027.4320.23Price / SalesN/A4,210.48422.11118.64Price / CashN/A13.1936.8958.07Price / BookN/A43.028.045.67Net Income-$43.77M-$92.79M$3.18B$249.13M 9 Meters Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220TTNPTitan Pharmaceuticals0.3358 of 5 stars$4.49+5.3%N/A-17.1%$4.08M$180K-0.9810Gap DownMBRXMoleculin Biotech2.9252 of 5 stars$0.28+3.7%$4.00+1,308.5%-90.4%$4.03MN/A0.0020Positive NewsHigh Trading VolumeDRMADermata Therapeutics1.5026 of 5 stars$0.63-0.6%$3.00+377.7%-70.1%$3.98MN/A-0.048Positive NewsGap UpEVOKEvoke PharmaN/A$2.65+6.0%N/A-57.9%$3.95M$10.25M-0.924Positive NewsVIVSVivoSim LabsN/A$1.50+2.0%N/AN/A$3.90M$140K-0.1520Positive NewsTHARTharimmune3.3738 of 5 stars$1.43+8.8%$17.00+1,093.0%-44.7%$3.79MN/A-0.182Positive NewsPLRZPolyrizonN/A$0.71+2.9%N/AN/A$3.77MN/A0.00N/ANews CoveragePositive NewsGap DownCEROCERo Therapeutics3.301 of 5 stars$9.47+16.0%$45.00+375.4%-98.2%$3.75MN/A0.008Gap UpHigh Trading VolumeCANFCan-Fite BioPharma3.3171 of 5 stars$1.06+1.0%$14.00+1,227.0%-57.9%$3.74M$674K-0.598Gap UpCMNDClearmind Medicine0.6124 of 5 stars$0.87-2.2%N/A-26.8%$3.72MN/A-0.79N/A Related Companies and Tools Related Companies TTNP Alternatives MBRX Alternatives DRMA Alternatives EVOK Alternatives VIVS Alternatives THAR Alternatives PLRZ Alternatives CERO Alternatives CANF Alternatives CMND Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMTR) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NMTR Stock Alerts